Clinical Trial Update: Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of PL001, a CD19 CAR-T cell therapy, for relapsed or refractory B-cell lymphoma. The trial is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Grade 3a
• Follicular Lymphoma Grade 3b
• Large B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• PL001 CD19 CAR-T (CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) targeting CD19)

Snippet

Sponsor: Pell Bio-Med Technology Co., Ltd. | Conditions: Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING